Drug Profile
Chronic obstructive pulmonary disease therapeutic - Dr. Reddy's Laboratories/Pulmagen Therapeutics
Latest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator Dr Reddys Laboratories; Pulmagen Therapeutics
- Developer Dr Reddys Laboratories
- Class
- Mechanism of Action
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Chronic obstructive pulmonary disease
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for phase-I development in Chronic-obstructive-pulmonary-disease in India (Inhalation)